Other substances

Quercetin

A natural flavonoid.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Natural product

Supporting references

Contradictory references

141

AI-suggested references

Clinical trials

General information

Quercetin is a major bioflavonoid in the human diet. Various biological activities of quercetin have been proposed, e. g. anti-proliferative, anti-inflammatory, or anti-allergy (NCIt).

Quercetin on DrugBank
Quercetin on PubChem
Quercetin on Wikipedia

C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Evaluation of Flavonoids as 2019-nCoV Cell Entry Inhibitor Through Molecular Docking and Pharmacological Analysis Preprint In silico	in silico			Apr/06/2020
In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2 Small molecule In silico Screening	in silico	3.26	Predicted to block SARS-CoV-2 spike protein interaction sites.	Aug/06/2020
Screening of Therapeutic Agents for COVID-19 Using Machine Learning and Ensemble Docking Studies Screening	in silico	6.71	Predicted to bind the SARS-CoV-2 spike protein or spike protein:ACE2 interface.	Aug/05/2020
In-silico screening of plant-derived antivirals against main protease, 3CLpro and endoribonuclease, NSP15 proteins of SARS-CoV-2 3CLpro nsp15 Small molecule In silico	in silico	3.22	Predicted to inhibit the SARS-CoV-2 3C-like protease and the nsp15 endoribonuclease.	Sep/08/2020
Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study Spike protein 3CLpro Small molecule In silico Screening	in silico	3.22	Predicted to inhibit the SARS-CoV-2 3C-like protease and bind to the spike protein.	Sep/18/2020
Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6 IL-6 Small molecule In silico	in silico	2.94	Predicted to downregulate IL-6.	Nov/04/2020
Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study 3CLpro Small molecule Animal model Moderate severity Mild severity Mixed substance Cohort study In silico	in silico; patients; BALB/c mice (HCoV-229E virus infection only)	4.27	Predicted to bind the SARS-CoV-2 3C-like protease.	Oct/22/2020
In silico screening of potential anti–COVID-19 bioactive natural constituents from food sources by molecular docking 3CLpro ACE2 Small molecule In silico	in silico	3.64	Predicted to be effective as an anti-COVID-19 dietary supplement.	Nov/07/2020
Evaluation of certain medicinal plants compounds as new potential inhibitors of novel corona virus (COVID-19) using molecular docking analysis 3CLpro Small molecule In silico	in silico		Predicted to inhibit the SARS-CoV-2 3C-like protease.	Jan/06/2021
Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis 3CLpro Small molecule In silico	in silico	1.80	Predicted to allosterically inhibit the SARS-CoV-2 3C-like protease.	Jan/12/2021
Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies Spike protein 3CLpro RdRpol ACE2 Small molecule In silico	in silico	4.55	Predicted to interact with the SARS-CoV-2 3C-like protease.	Feb/03/2021
A network pharmacology based approach for predicting active ingredients and potential mechanism of Lianhuaqingwen capsule in treating COVID-19 3CLpro Small molecule In silico	in silico	2.52	Predicted to bind SARS-CoV-2 3C-like protease.	Feb/24/2021

AI-suggested references

Link	Publication date
Theoretical Study of the Molecular Mechanism of Maxingyigan Decoction Against COVID-19: Network Pharmacology-based Strategy.	Oct/08/2020
Molecular modelling identification of phytocompounds from selected African botanicals as promising therapeutics against druggable human host cell targets of SARS-CoV-2.	Jun/11/2021
Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19.	Nov/21/2020
Therapeutic mechanism of Xiaoqinglong decoction against COVID-19 based on network pharmacology and molecular docking technology.	Feb/03/2022
Aframomum melegueta secondary metabolites exhibit polypharmacology against SARS-CoV-2 drug targets: in vitro validation of furin inhibition.	May/17/2021
Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections.	Jan/19/2021
The spike protein of SARS-CoV-2 virus induces heme oxygenase-1: Pathophysiologic implications.	Dec/14/2021
Arq Ajib - a wonder Unani formulation for inhibiting SARS-CoV-2 spike glycoprotein and main protease - an in silico approach.	Oct/22/2021
Evidence that Ginkgo Biloba could use in the influenza and coronavirus COVID-19 infections.	Feb/16/2021
Study on the Mechanism of treating COVID-19 with Shenqi Wan based on Network Pharmacology.	May/17/2021
Network analysis, sequence and structure dynamics of key proteins of coronavirus and human host, and molecular docking of selected phytochemicals of nine medicinal plants.	Jul/20/2020
Mechanistic Aspects of Medicinal Plants and Secondary Metabolites against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).	Jul/07/2021
Potential of (Citrus nobilis Lour x Citrus deliciosa Tenora) metabolites on COVID-19 virus main protease supported by in silico analysis.	May/05/2021
Molecular mechanisms revealed by network pharmacology of Xuebijing on the treatment of acute respiratory distress syndrome caused by novel coronavirus infection.	Jun/05/2020
Phytonutrient Inhibitors of SARS-CoV-2/NSP5-Encoded Main Protease (Mpro) Autocleavage Enzyme Critical for COVID-19 Pathogenesis.	Apr/01/2022
Identification of potential phytochemicals from Citrus Limon against main protease of SARS-CoV-2: molecular docking, molecular dynamic simulations and quantum computations.	Jul/19/2021
Potential of Ficus microcarpa metabolites against SARS-CoV-2 main protease supported by docking studies.	Sep/01/2021
Exploring the Potential Mechanism of Shufeng Jiedu Capsule for Treating COVID-19 by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation.	Mar/11/2020
Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.	Feb/08/2022
In silico study of potential immunonutrient-based sports supplements against COVID-19 via targeting ACE2 inhibition using molecular docking and molecular dynamics simulations.	Dec/21/2021
Quercetin Phytosome as a potential candidate for managing COVID-19.	Oct/05/2020
Zinc2+ ion inhibits SARS-CoV-2 main protease and viral replication in vitro.	Aug/03/2020
Phytocompounds from Anvillea radiata as promising anti-Covid-19 drugs: in silico studies and in vivo safety assessment.	Jan/02/2022
Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19.	Nov/18/2020
Virus-induced senescence is a driver and therapeutic target in COVID-19.	Sep/13/2021
Insights into the Antimicrobial, Antioxidant, Anti-SARS-CoV-2 and Cytotoxic Activities of Pistacia lentiscus Bark and Phytochemical Profile; In Silico and In Vitro Study.	May/09/2022
Potential Inhibitors of SARS-CoV-2 from Neocarya macrophylla (Sabine) Prance ex F. White: Chemoinformatic and Molecular Modeling Studies for Three Key Targets	Jun/05/2022
Computational Analysis Illustrates the Mechanism of Qingfei Paidu Decoction in Blocking the Transition of COVID-19 Patients from Mild to Severe Stage	May/13/2021
Exploring the treatment of COVID-19 with Yinqiao powder based on network pharmacology	Jan/15/2021
In silico identification of SARS-CoV-2 cell entry inhibitors from selected natural antivirals.	Sep/29/2021
Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease	May/27/2020
In silico evaluation of Vitis amurensis Rupr. polyphenol compounds for their inhibition potency against CoVID-19 main enzymes Mpro and RdRp	Feb/28/2021
In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein	May/29/2020
Perspectives on plant flavonoid quercetin-based drugs for novel SARS-CoV-2.	Mar/24/2021
In silico docking analysis revealed the potential of phytochemicals present in Phyllanthus amarus and Andrographis paniculata, used in Ayurveda medicine in inhibiting SARS-CoV-2.	Jan/11/2021
Phytochemicals present in Indian ginseng possess potential to inhibit SARS-CoV-2 virulence: A molecular docking and MD simulation study.	May/24/2021
A Review of Medicinal Plants with Antiviral Activity Available in Bangladesh and Mechanistic Insight Into Their Bioactive Metabolites on SARS-CoV-2, HIV and HBV.	Nov/08/2021
New tale on LianHuaQingWen: IL6R/IL6/IL6ST complex is a potential target for COVID-19 treatment	Nov/03/2021
Quercetin/Zinc complex and stem cells: A new drug therapy to ameliorate glycometabolic control and pulmonary dysfunction in diabetes mellitus: Structural characterization and genetic studies	Mar/04/2021
Therapeutic mechanism of Toujie Quwen granules in COVID-19 based on network pharmacology.	Sep/24/2020
The vital role of animal, marine, and microbial natural products against COVID-19	Mar/03/2022
Virtual Screening and Molecular Docking to Study the Mechanism of Chinese Medicines in the Treatment of Coronavirus Infection	Feb/24/2022
Computational screening of phytochemicals from three medicinal plants as inhibitors of transmembrane protease serine 2 implicated in SARS-CoV-2 infection.	Sep/29/2021
A Network Pharmacology Study to Uncover the Multiple Molecular Mechanism of the Chinese Patent Medicine Toujiequwen Granules in the Treatment of Corona Virus Disease 2019 (COVID-19).	Apr/20/2021
Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF-kappaB signaling pathway.	Oct/01/2021
Network pharmacology, molecular docking integrated surface plasmon resonance technology reveals the mechanism of Toujie Quwen Granules against coronavirus disease 2019 pneumonia	Feb/01/2021
Chinese herbal compounds against SARS-CoV-2: Puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor.	Nov/11/2020
Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2.	Jun/15/2021
Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study.	Jun/08/2021
Isoquercetin as an Anti-Covid-19 Medication: A Potential to Realize	Apr/06/2022
A review of natural products, their effects on SARS-CoV-2 and their utility as lead compounds in the discovery of drugs for the treatment of COVID-19	Nov/28/2020
Antiviral Activity of Vitis vinifera Leaf Extract against SARS-CoV-2 and HSV-1	May/28/2020
Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)	Jun/19/2020
Molecular docking and pharmacokinetic studies of phytocompounds from Nigerian Medicinal Plants as promising inhibitory agents against SARS-CoV-2 methyltransferase (nsp16)	May/20/2020
Investigation of potential inhibitor properties of ethanolic propolis extracts against ACE-II receptors for COVID-19 treatment by molecular docking study	Mar/10/2021
In Silico Screening of Natural Products Isolated from Mexican Herbal Medicines against COVID-19	Mar/15/2021
Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19	Jul/08/2020
Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19	Nov/03/2020
Exploring the interaction of quercetin-3-O-sophoroside with SARS-CoV-2 main proteins by theoretical studies: A probable prelude to control some variants of coronavirus including Delta.	Jul/28/2021
Analysis of the mechanism of Shufeng Jiedu capsule prevention and treatment for COVID-19 by network pharmacology tools.	Oct/30/2020
Traditional Chinese medicine network pharmacology study on exploring the mechanism of Xuebijing Injection in the treatment of coronavirus disease 2019	Dec/29/2020
The potential of BEN815 as an anti-inflammatory, antiviral and antioxidant agent for the treatment of COVID-19.	Mar/18/2021
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial	May/02/2022
Promising Effects of 3-Month Period of Quercetin Phytosome Supplementation in the Prevention of Symptomatic COVID-19 Disease in Healthcare Workers: A Pilot Study	Jan/04/2022
Analysis of the active components and mechanism of Shufeng Jiedu capsule against COVID-19 based on network pharmacology and molecular docking	Jan/15/2022
Flavonoids from Siparuna cristata as Potential Inhibitors of SARS-CoV-2 Replication.	Jul/20/2021
Rescuing the Host Immune System by Targeting the Immune Evasion Complex ORF8-IRF3 in SARS-CoV-2 Infection with Natural Products Using Molecular Modeling Approaches	Dec/03/2021
Molecular basis of quercetin as a plausible common denominator of macrophage-cholesterol-fenofibrate dependent potential COVID-19 treatment axis.	Jun/12/2021
Treatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial	Dec/24/2021
Network pharmacology-based predictions of active components and pharmacological mechanisms of Artemisia annua L. for the treatment of the novel Corona virus disease 2019 (COVID-19)	Mar/03/2022
Molecular Docking and ADMET Prediction of Natural Compounds towards SARS Spike Glycoprotein-Human Angiotensin-Converting Enzyme 2 and SARS-CoV-2 Main Protease.	Sep/01/2021
Clinical data mining reveals Gancao-Banxia as a potential herbal pair against moderate COVID-19 by dual binding to IL-6/STAT3	Mar/26/2022
Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside.	May/28/2021
Conducting the RBD of SARS-CoV-2 Omicron Variant with Phytoconstituents from Euphorbia dendroides to Repudiate the Binding of Spike Glycoprotein Using Computational Molecular Search and Simulation Approach	Sep/06/2021
Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro	Apr/13/2021
Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction	Jun/25/2020
Anti-inflammatory potential of Quercetin in COVID-19 treatment	Jan/28/2021
Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp)	Sep/30/2020
Inhibitory activity of quercetin, its metabolite, and standard antiviral drugs towards enzymes essential for SARS-CoV-2: the role of acid-base equilibria.	Jan/12/2021
Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.	Aug/01/2020
Network pharmacology and RNA-sequencing reveal the molecular mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction	Nov/22/2021
Potential role of medicinal plants and their constituents in the mitigation of SARS-CoV-2: identifying related therapeutic targets using network pharmacology and molecular docking analyses	Oct/13/2020
Prospecting for Cressa cretica to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2	May/22/2020
Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein	Jan/29/2021
Identifying the molecular targets and mechanisms of xuebijing injection for the treatment of COVID-19 via network pharmacology and molecular docking	Mar/06/2021
Phytoconstituents, In Vitro Anti-Infective Activity of Buddleja indica Lam., and In Silico Evaluation of its SARS-CoV-2 Inhibitory Potential	Apr/12/2021
Flavonoid compounds of buah merah (Pandanus conoideus Lamk) as a potent SARS-CoV-2 main protease inhibitor: in silico approach	Aug/10/2021
New chalcone derivatives as effective against SARS-CoV-2 agent	Sep/25/2021
Epigallocatechin Gallate Inhibits the Uridylate-Specific Endoribonuclease Nsp15 and Efficiently Neutralizes the SARS-CoV-2 Strain	May/21/2021
Natural product-derived phytochemicals as potential agents against coronaviruses: A review	Apr/30/2020
A molecular docking study of SARS-CoV-2 main protease against phytochemicals of Boerhavia diffusa Linn. for novel COVID-19 drug discovery.	Mar/18/2021
Mechanism of Dayuanyin in the treatment of coronavirus disease 2019 based on network pharmacology and molecular docking	Jun/12/2020
In Silico Screening of Natural Products as Potential Inhibitors of SARS-CoV-2 Using Molecular Docking Simulation	Mar/15/2022
Flavonoids as Promising Antiviral Agents against SARS-CoV-2 Infection: A Mechanistic Review	Apr/08/2022
Roles of flavonoids against coronavirus infection.	Jul/28/2020
In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2	Mar/09/2022
Molecular docking and dynamics studies on propolis sulabiroin-A as a potential inhibitor of SARS-CoV-2.	Nov/15/2021
In silico screening of potent bioactive compounds from honeybee products against COVID-19 target enzymes	May/02/2021
Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole	Jul/02/2020
Potent antiviral activity of Agrimonia pilosa, Galla rhois, and their components against SARS-CoV-2.	Jul/23/2021
Phytogenic Products and Phytochemicals as a Candidate Strategy to Improve Tolerance to Coronavirus	Oct/20/2020
Rational design of flavonoid based potential inhibitors targeting SARS-CoV 3CL protease for the treatment of COVID-19.	Apr/07/2021
Therapeutic potential of phytoconstituents of edible fruits in combating emerging viral infections	Jul/08/2021
Inhibition of SARS-CoV-2 main protease by phenolic compounds from Manilkara hexandra (Roxb.) Dubard assisted by metabolite profiling and in silico virtual screening	Apr/17/2022
Using a System Pharmacology Method to Search for the Potential Targets and Pathways of Yinqiaosan against COVID-19	Mar/15/2022
Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human	May/21/2020
Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development	May/03/2022
Predictive medicinal metabolites from Momordica dioica against comorbidity related proteins of SARS-CoV-2 infections	May/08/2022
A Network-Biology led Computational Drug repurposing Strategy to prioritize therapeutic options for COVID-19	May/11/2022
Quercetin for COVID-19 and DENGUE co-infection: a potential therapeutic strategy of targeting critical host signal pathways triggered by SARS-CoV-2 and DENV	Jan/06/2021
Network pharmacology and molecular docking analysis on mechanisms of Tibetan Hongjingtian (Rhodiola crenulata) in the treatment of COVID-19	Jul/28/2021
Quercetin as a potential treatment for COVID-19-induced acute kidney injury: Based on network pharmacology and molecular docking study	Mar/18/2022
Potential Natural Products Against Respiratory Viruses: A Perspective to Develop Anti-COVID-19 Medicines	Sep/18/2021
Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants	Jan/21/2022
Quercetin as a Natural Therapeutic Candidate for the Treatment of Influenza Virus	Jul/02/2020
Flavonoids are promising safe therapy against COVID-19.	May/22/2021
Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor	May/24/2020
Mechanistic Aspects and Therapeutic Potential of Quercetin against COVID-19-Associated Acute Kidney Injury	Dec/07/2020
Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment	Feb/15/2021
Potential bioactive glycosylated flavonoids as SARS-CoV-2 main protease inhibitors: A molecular docking and simulation studies	Oct/15/2020
Seleno-Functionalization of Quercetin Improves the Non-Covalent Inhibition of Mpro and Its Antiviral Activity in Cells against SARS-CoV-2	Jun/30/2021
Natural Polyphenols as Immunomodulators to Rescue Immune Response Homeostasis: Quercetin as a Research Model against Severe COVID-19	Sep/25/2021
Natural Compounds Inhibit SARS-CoV-2 nsp13 Unwinding and ATPase Enzyme Activities.	Apr/01/2022
Potential mechanisms of Chinese Herbal Medicine that implicated in the treatment of COVID-19 related renal injury.	Aug/10/2020
Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19)	May/21/2020
Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach	Jun/22/2020
Inhibition of drug-metabolizing enzymes by Jingyin granules: implications of herb-drug interactions in antiviral therapy	Jun/28/2021
Garlic (Allium sativum L.): a potential unique therapeutic food rich in organosulfur and flavonoid compounds to fight with COVID-19	Sep/04/2021
Network Pharmacology Analysis to Identify Phytochemicals in Traditional Chinese Medicines That May Regulate ACE2 for the Treatment of COVID-19	Nov/05/2020
Exploration of the Mechanism of Lianhua Qingwen in Treating Influenza Virus Pneumonia and New Coronavirus Pneumonia with the Concept of "Different Diseases with the Same Treatment" Based on Network Pharmacology	May/25/2021
Quercetin and Its Metabolites Inhibit Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Activity	Nov/12/2020
Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease	Jun/29/2020
Undifferentiated In Vitro Cultured Actinidia deliciosa as Cell Factory for the Production of Quercetin Glycosides	Nov/18/2021
Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2	Mar/29/2020
Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial	Jun/01/2020
Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E.	Apr/12/2022
Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)	Nov/10/2020
Inhibition of SARS CoV Envelope Protein by Flavonoids and Classical Viroporin Inhibitors.	Jul/08/2021
Active site-specific quantum tunneling of hACE2 receptor to assess its complexing poses with selective bioactive compounds in co-suppressing SARS-CoV-2 influx and subsequent cardiac injury	May/15/2020
Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants	Nov/30/2020
Antiviral, immunomodulatory, and anticoagulant effects of quercetin and its derivatives: Potential role in prevention and management of COVID-19	Sep/20/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT05130671	Nutritional Supplementation of Flavonoids Quercetin and Curcumin for Early Mild Symptoms of COVID-19	Completed	Not Applicable	Oct/25/2021	Dec/31/2021
Alternative id - 785/RC/KEMU/25.10.2021 Interventions - Drug: Standard of care\|Dietary Supplement: Investigational treatment Study type - Interventional Study results - No Results Available Locations - King Edward Medical University Teaching Hospital, Lahore, Punjab, Pakistan Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 50 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Testing negative for SARS-CoV-2 by Reverse Transcription Polymerase Chain Reaction (RT-PCR)\|COVID-19 symptoms improvement\|Improvement in CRP level\|Improvement in D-dimers level\|Improvement in LDH levels\|Improvement in ferritin levels\|Improvement in full blood count (CBC)
NCT04861298	Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early Mild Symptoms of COVID-19	Completed	Not Applicable	Jan/11/2021	Aug/29/2021
Alternative id - 192/RC/KEMU Interventions - Drug: standard of care for COVID-19 as per the hospital guidelines\|Dietary Supplement: Quercetin Phytosome (QP) Study type - Interventional Study results - No Results Available Locations - King Edward Medical University Teaching Hospital, Lahore, Punjab, Pakistan Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 100 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Testing negative for SARS-CoV-2 by RT-PCR with symptoms improvement\|Percentage of subjects that require hospitalisation\|Improvement in CRP\|Improvement in D-Dimers\|Improvement in LDH\|Improvement in Ferritin\|Improvement in CBC
NCT04853199	Quercetin In The Treatment Of SARS-COV 2	Recruiting	Early Phase 1	Jun/01/2021	Aug/30/2021
Alternative id - QUERCOV Interventions - Drug: Quercetin\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - HU Sahloul, sousse, Tunisia, Sousse, Itinéraire Ceinture Cité Sahloul, Tunisia\|Riadh Boukef, Sahloul, Sousse, Tunisia Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 200 Age - 18 Years and older (Adult, Older Adult) Outcome measures - The Efficacy measurment\|DEATH\|HOSPITALISATION
NCT04377789	Effect of Quercetin on Prophylaxis and Treatment of COVID-19	Completed	Not Applicable	Mar/20/2020	Aug/31/2020
Alternative id - KSSEAH--0058 Interventions - Dietary Supplement: Quercetin Prophylaxis\|Dietary Supplement: Quercetin Treatment Study type - Interventional Study results - No Results Available Locations - Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 447 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Prevalence of COVID-19 calculated using a questionnaire\|Standardized Mortality rate\|Morbidity rate
NCT05008003	Study to Investigate Treatment Benefits of Combination of Vit D3, Quercetin and Curcumin for Early Mild Symptoms of COVID-19	Recruiting	Not Applicable	Aug/06/2021	Mar/31/2022
Alternative id - CQC/COVID/08-2021 Interventions - Drug: Standard of care\|Dietary Supplement: Combination of oral quercetin, curcumin and vitamin D3 Study type - Interventional Study results - No Results Available Locations - Ayub Teaching Hospital, Abbottabad, Khyber Pakhtunkhwa, Pakistan Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 50 Age - 18 Years and older (Adult, Older Adult) Outcome measures - SARS-CoV-2 Negativity by RT-PCR\|COVID-19 symptoms improvement\|Changes in CRP level\|Changes in D-dimer level\|Changes in LDH level\|Changes in ferritin level\|Changes in full blood count
NCT04851821	The Effectiveness of Phytotherapy in SARS-COV2(COVID-19)	Completed	Phase 1	Jan/04/2021	Jun/30/2021
Alternative id - Quercetix Interventions - Drug: Quercetin Study type - Interventional Study results - No Results Available Locations - Riadh Boukef, Sahloul, Sousse, Tunisia Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Care Provider)\|Primary Purpose: Treatment Enrollment - 80 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Number of patients\|disappearance of symptoms\|adverse reaction
NCT04578158	Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19	Completed	Phase 3	Sep/29/2020	Apr/15/2021
Alternative id - LUMHS/REC/894 Interventions - Drug: Standard COVID-19 care\|Dietary Supplement: Quercetin Phytosome Study type - Interventional Study results - No Results Available Locations - Liaquat University Hospital, Jāmshoro, Sindh, Pakistan Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 152 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Percentage of subjects with COVID-19 disease progression
NCT04733651	Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19	Not yet recruiting	Phase 2	Feb/20/2021	Aug/15/2021
Alternative id - 22-2021 Interventions - Drug: Hospital standard of care for COVID-19\|Drug: Isoquercetin Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 250 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Disease progression, defined as WHO Clinical Progression Scale score of ≥ 6, at any time from day 1 to day 28\|Disease recovery, defined as WHO Progression Scale score of ≤ 2, at day 28
NCT05037240	Quercetin in the Prevention of Covid-19 Infection	Completed	Not Applicable	Jan/12/2021	May/25/2021
Alternative id - 1222/01022021 Interventions - Dietary Supplement: Quercetin\|Combination Product: Placebo Study type - Interventional Study results - No Results Available Locations - Mariangela Rondanelli, Pavia, Italy Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 80 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Prevention of Covid-19 infection
NCT04536090	Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19	Not yet recruiting	Phase 2	Jan/01/2022	Jun/01/2023
Alternative id - IRCM-IQC-001 Interventions - Drug: Isoquercetin (IQC-950AN) Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 150 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Disease Progression\|Changes in viral load from baseline to end of treatment - Mean viral load\|Changes in viral load from baseline to end of treatment - Area under the viral load vs. time profiles\|Changes in viral load from baseline to end of treatment - Time profile of viral load\|Changes in viral load from baseline to end of treatment - Percentage of patients that are viral negative\|Disease Recovery\|Change in WHO Clinical Progression Scale score\|Incidence of all-cause mortality\|Progression to supplementary oxygen requirement\|Incidence of mechanical ventilation\|Incidence of ICU admission\|Time to hospital discharge\|Changes in serum C reactive protein levels (CRP)\|Changes in D-dimer levels\|Changes in soluble low-density lipoprotein receptor (sLDLR) expression and proprotein convertase subtilisin/kexin type 9 (PCSK9) and soluble angiotensin converting enzyme 2 (sACE2) levels\|Changes in LDL-cholesterol\|Changes in creatinine\|Changes in liver enzymes
NCT04622865	Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19	Recruiting	Phase 2	Jun/01/2020	Jun/01/2022
Alternative id - AB20001\|2020-001635-27 Interventions - Drug: Masitinib\|Drug: Isoquercetin\|Drug: Best Supportive Care Study type - Interventional Study results - No Results Available Locations - Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France\|Le Tripode, Groupe hospitalier Pellegrin CHU de Bordeaux, Bordeaux, France\|CHU Clermont-Ferrand: Site Gabriel-Montpied, Clermont-Ferrand, France\|Hopital Nord, AP-HM, Marseille, France\|CHR Orleans, Hopital de la Source, Orléans, France\|Hopital Larrey, CHU du Toulouse, Toulouse, France Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 200 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Clinical status of patients at day-15 using a 7-point ordinal scale
NCT04468139	The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19	Recruiting	Phase 4	Jun/20/2020	Jul/30/2020
Alternative id - 20-95M Interventions - Drug: Quercetin\|Dietary Supplement: bromelain\|Drug: Zinc\|Drug: Vitamin C Study type - Interventional Study results - No Results Available Locations - Ministry of health.First health cluster ,Riaydh, Riyadh, Saudi Arabia Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 60 Age - 18 Years and older (Adult, Older Adult) Outcome measures - days of stay at hospital after treatment and discharge\|serum zinc before and after treatment\|questionnaire including parameters like BMI,,smoking , underling diseases, immunological treatment ,\|day of negative conversion for nasopharyngeal swab for rt-PCR FOR covid-19

Export (.csv)